# Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

> **NCT05070845** · PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 91 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** PF-06835375

## Key facts

- **NCT ID:** NCT05070845
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-02
- **Primary completion:** 2028-08-02
- **Final completion:** 2028-08-02
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070845, "Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05070845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*